Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
BMC Cancer. 2011 Jul 22;11:309. doi: 10.1186/1471-2407-11-309.
E7080 is an orally active multi-targeted kinase inhibitor whose targets include vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptor (FGFR) and platelet derived growth factor receptors (PDGFR). It has been shown to inhibit tumor angiogenesis by targeting endothelial cells. A number of the targets of E7080 are also expressed on tumor cells and here we have looked at the direct effects of E7080 on tumor cell behavior.
Using a panel of human tumor cell lines we determined the effect of E7080 on cell proliferation, migration and invasion. Inhibition of FGFR and PDGFR signaling in the cells was measured.
E7080 had little effect on tumor cell proliferation. However, it blocked migration and invasion at concentrations that inhibited FGFR and PDGFR signaling. Knock-down of PDGFR-β in U2OS osteosarcoma cells also inhibited cell migration which, could not be further inhibited in the presence of E7080. Furthermore, E7080 could not inhibit the migration of a PDGFR negative cell line.
E7080 does not significantly affect tumor cell proliferation but can inhibit their migration and invasion at concentrations that both inhibit its known targets and are achievable clinically.
E7080 是一种口服活性的多靶点激酶抑制剂,其靶点包括血管内皮生长因子受体(VEGFR)、成纤维细胞生长因子受体(FGFR)和血小板衍生生长因子受体(PDGFR)。它通过靶向内皮细胞来抑制肿瘤血管生成。E7080 的许多靶点也在肿瘤细胞上表达,在这里我们研究了 E7080 对肿瘤细胞行为的直接影响。
我们使用一组人肿瘤细胞系来确定 E7080 对细胞增殖、迁移和侵袭的影响。测量了细胞中 FGFR 和 PDGFR 信号的抑制作用。
E7080 对肿瘤细胞增殖的影响很小。然而,它在抑制 FGFR 和 PDGFR 信号的浓度下阻断了迁移和侵袭。在 U2OS 骨肉瘤细胞中敲低 PDGFR-β 也抑制了细胞迁移,而在 E7080 存在的情况下,这种抑制作用不能进一步增强。此外,E7080 不能抑制 PDGFR 阴性细胞系的迁移。
E7080 对肿瘤细胞增殖的影响不大,但在抑制其已知靶点的浓度下,可抑制肿瘤细胞的迁移和侵袭,而这些浓度在临床上是可达到的。